RFK Jr.'s '14 peptides' FDA claim: what's real and what's hype

What did @noah.jay_ actually say?

The short version: @noah.jay_ claims RFK announced on the Joe Rogan podcast that 14 peptides are "about to be FDA approved," then uses that as a launching pad to talk about two stacks he's personally used. He names "Glow" as a combination of GHK-Cu, BPC-157, and TB-500, credits it with tissue repair and skin benefits, and says CJC-1295 plus ipamorelin ("CJC plus IPA") helps with sleep, recovery, and lean mass preservation even in a caloric deficit. He's clear this is "not medical advice" and frames everything through his own 53-pound weight loss transformation.

To his credit, he's not selling a specific product in this clip. But the framing that a government official's podcast appearance equals imminent FDA approval is doing a lot of heavy lifting here, and it deserves a closer look.

Does the science back this up?

For the peptides themselves, there's real but limited evidence. For the FDA approval claim, there's essentially none in the form presented.

BPC-157 has shown tissue-healing effects in rodent models, including tendon and ligament repair (Sikiric et al., 2018, Current Pharmaceutical Design). TB-500, the synthetic fragment of thymosin beta-4, has similar preclinical data on angiogenesis and wound healing (Goldstein & Kleinman, 2015, Annals of the New York Academy of Sciences). GHK-Cu has published data on collagen synthesis and skin remodeling (Pickart et al., 2015, Journal of Aging Research). That all sounds promising. But preclinical rodent data and small human trials are not the same as FDA-approved indications. None of these three compounds have cleared Phase III human trials for the uses being described.

CJC-1295 and ipamorelin are growth hormone secretagogues. There is evidence they raise IGF-1 and GH levels (Teichman et al., 2006, Journal of Clinical Endocrinology and Metabolism), and ipamorelin's selectivity is genuinely notable compared to older GH secretagogues. The claim that this stack "blunts inflammation without blunting growth" is a popular gym-culture talking point, but direct human trial data supporting that specific combination for body composition in a deficit is thin.

What did they get wrong (or right)?

The FDA approval framing is the biggest problem here. RFK Jr. has made public statements about wanting to reform peptide regulation, and there have been ongoing discussions at HHS and FDA about the status of certain compounded peptides. But "announced on the Joe Rogan podcast" does not equal a regulatory action. FDA approvals require a formal New Drug Application process, clinical trial data, and published Federal Register notices. A podcast interview is not that.

The claim that 14 peptides are "about to be FDA approved" is unverifiable at best and misleading at worst. What's more likely being referenced is a policy conversation about removing certain peptides from the FDA's "Category 2" bulk drug substances list, which would affect compounding pharmacies, not grant the peptides formal drug approval. Those are very different things.

What he got right: the general mechanisms he describes for BPC-157 and TB-500 (increased blood flow, tissue repair for tendons and ligaments) are consistent with the available preclinical literature. Calling CJC-1295 plus ipamorelin a stack associated with sleep and recovery is broadly accurate based on GH secretagogue pharmacology. His disclaimer that this is not medical advice is appropriate, even if the overall framing makes the information sound more settled than it is.

What should you actually know?

If you're considering any of these compounds, the regulatory situation matters more than most creators let on. BPC-157, TB-500, and the other peptides discussed here are currently available through compounding pharmacies in some jurisdictions, but their legal and regulatory status has been actively shifting. The FDA placed several peptides on a restricted list for compounding in 2023, and that list has been contested by compounding pharmacy trade groups and some physicians.

The phrase "FDA approved" specifically means a drug has gone through the full NDA or BLA process. None of these peptides have done that for the indications being discussed. A policy change that allows compounding pharmacies to use a substance is not the same thing as FDA approval, and conflating the two gives consumers a false sense of established safety and efficacy.

If you want to explore peptide therapy, that conversation belongs with a licensed provider who can review your bloodwork, health history, and goals. The stack descriptions in this video are based on one person's experience and gym-culture consensus, not clinical protocols.